Venezuela’s national government has changed its policy with regard to the pharmaceutical sector. This year, government authorities have taken a number of steps, stripping the sector of its "priority" treatment, writes Roberto Deniz in the El Universal newspaper.
The Venezuelan pharmaceutical market is the third largest in Latin America, and was valued at $6.8 billion in 2010, an increase of 32.7% on the previous year.
Last week, the government put 70% of final products from the pharmaceutical and laboratory sector in list 2 of the Foreign Exchange Administration Commission (Cadivi). Therefore, the requirements to import these products increased and now the pharmaceutical sector should process the Non-Production certificate (CNP) before requesting dollars.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze